DPPG₂-Based Thermosensitive Liposomes with Encapsulated Doxorubicin Combined with Hyperthermia Lead to Higher Doxorubicin Concentrations in the Bladder Compared to Conventional Application in Pigs: A Rationale for the Treatment of Muscle-Invasive Bladder Cancer

References

• Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer. 2013;49(6):1374–1403. doi:10.1016/j.ejca.2012.12.027
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in non-muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1–3 years of maintenance bacillus calmette-guerin. Eur Urol. 2016;69(1):60–69. doi:10.1016/j.eururo.2015.06.045
   PubMed Web of Science ®Google Scholar
• Babjuk M, Burger M, Compérat E, et al. EAU guideline non-muscle-invasive bladder cancer. Edn. presented at the EAU Annual Congress Amsterdam 2020: EAU guidelines office: Arnhem, the Netherlands; 2020. Available from: http://uroweb.org/guidelines/compilations-of-all-guidelines/. Accessed August 20, 2020.
   Google Scholar
• Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1000 neobladders: the 90-day complication rate. J Urol. 2010;184(3):990–994; quiz 1235.
   PubMedGoogle Scholar
• Hautmann RE, Abol-Enein H, Davidsson T, et al. ICUD-EAU international consultation on bladder cancer 2012: urinary diversion. Eur Urol. 2013;63(1):67–80. doi:10.1016/j.eururo.2012.08.050
   PubMed Web of Science ®Google Scholar
• Nielsen ME, Mallin K, Weaver MA, et al. Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the National Cancer Data Base. BJU Int. 2014;114(1):46–55.
   PubMed Web of Science ®Google Scholar
• Smith AB, Jaeger B, Pinheiro LC, et al. Impact of bladder cancer on health-related quality of life. BJU Int. 2018;121(4):549–557.
   PubMed Web of Science ®Google Scholar
• Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018;3:7.
   PubMed Web of Science ®Google Scholar
• Farmacotherapeutisch Kompas: doxorubicin [website]. Available from: https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/d/doxorubicine. Accessed July 20, 2020.
   Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–6392.
   PubMed Web of Science ®Google Scholar
• Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71(8):1185–1198. doi:10.1111/jphp.13098
   PubMed Web of Science ®Google Scholar
• Administration USFaD. Doxil Highlights Of Prescribing Information. 2013.
   Google Scholar
• Bhowmik S, Bhowmick S, Maiti K, et al. Two multicenter Phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil((R)) or Caelyx((R)) in advanced ovarian cancer. Cancer Chemother Pharmacol. 2018;82(3):521–532. doi:10.1007/s00280-018-3643-3
   PubMed Web of Science ®Google Scholar
• O’Brien ME, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a Phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–449. doi:10.1093/annonc/mdh097
   PubMed Web of Science ®Google Scholar
• Judson I, Radford JA, Harris M, et al. Randomised Phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 2001;37(7):870–877. doi:10.1016/S0959-8049(01)00050-8
   PubMed Web of Science ®Google Scholar
• Rifkin RM, Gregory SA, Mohrbacher A, Hussein MA. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer. 2006;106(4):848–858. doi:10.1002/cncr.21662
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Pouli A, Zervas K, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol. 2003;14(7):1039–1044. doi:10.1093/annonc/mdg287
   PubMed Web of Science ®Google Scholar
• Harrington KJ, Mohammadtaghi S, Uster PS, et al. Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res. 2001;7(2):243–254.
   PubMed Web of Science ®Google Scholar
• Seynhaeve ALB, Dicheva BM, Hoving S, Koning GA, Ten Hagen TLM. Intact Doxil is taken up intracellularly and released doxorubicin sequesters in the lysosome: evaluated by in vitro/in vivo live cell imaging. J Control Release. 2013;172(1):330–340. doi:10.1016/j.jconrel.2013.08.034
   PubMed Web of Science ®Google Scholar
• Kneidl B, Peller M, Winter G, Lindner LH, Hossann M. Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomedicine. 2014;9:4387–4398.
   PubMed Web of Science ®Google Scholar
• Tak WY, Lin SM, Wang Y, et al. Phase III HEAT study adding lyso-thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions. Clin Cancer Res. 2018;24(1):73–83. doi:10.1158/1078-0432.CCR-16-2433
   PubMed Web of Science ®Google Scholar
• Mikhail AS, Negussie AH, Pritchard WF, et al. Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer. Int J Hyperthermia. 2017;33(7):733–740.
   PubMed Web of Science ®Google Scholar
• Lindner LH, Eichhorn ME, Eibl H, et al. Novel temperature-sensitive liposomes with prolonged circulation time. Clin Cancer Res. 2004;10(6):2168–2178. doi:10.1158/1078-0432.CCR-03-0035
   PubMed Web of Science ®Google Scholar
• Limmer S, Hahn J, Schmidt R, et al. Gemcitabine treatment of rat soft tissue sarcoma with phosphatidyldiglycerol-based thermosensitive liposomes. Pharm Res. 2014;31(9):2276–2286. doi:10.1007/s11095-014-1322-6
   PubMedGoogle Scholar
• Hossann M, Syunyaeva Z, Schmidt R, et al. Proteins and cholesterol lipid vesicles are mediators of drug release from thermosensitive liposomes. J Control Release. 2012;162(2):400–406. doi:10.1016/j.jconrel.2012.06.032
   PubMed Web of Science ®Google Scholar
• Zimmermann K, Hossann M, Hirschberger J, et al. A pilot trial of doxorubicin containing phosphatidyldiglycerol based thermosensitive liposomes in spontaneous feline soft tissue sarcoma. Int J Hyperthermia. 2017;33(2):178–190. doi:10.1080/02656736.2016.1230233
   PubMed Web of Science ®Google Scholar
• van Valenberg H, Colombo R, Witjes F. Intravesical radiofrequency-induced hyperthermia combined with chemotherapy for non-muscle-invasive bladder cancer. Int J Hyperthermia. 2016;32(4):351–362. doi:10.3109/02656736.2016.1140232
   PubMed Web of Science ®Google Scholar
• Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus calmette-guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046–1052. doi:10.1016/j.eururo.2016.01.006
   PubMed Web of Science ®Google Scholar
• Liem EI, Crezee H, de la Rosette JJ, de Reijke TM. Chemohyperthermia in non-muscle-invasive bladder cancer: an overview of the literature and recommendations. Int J Hyperthermia. 2016;32(4):363–373. doi:10.3109/02656736.2016.1155760
   PubMed Web of Science ®Google Scholar
• van Valenberg FJP, Witjes JA, Aklan B, de Jong SF, Zegers H, Oosterwijk E. Inducing intravesical hyperthermia of the ex-vivo porcine bladder wall: radiofrequency-induction versus recirculation using a custom-made device. Int J Hyperthermia. 2018;35(1):323–329. doi:10.1080/02656736.2018.1499046
   PubMed Web of Science ®Google Scholar
• Arends TJ, Falke J, Lammers RJ, et al. Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World J Urol. 2015;33(10):1411–1417. doi:10.1007/s00345-014-1458-3
   PubMed Web of Science ®Google Scholar
• van Valenberg FJP, van der Heijden AG, Lammers RJM, et al. Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. Int J Hyperthermia. 2017;1–6.
   Web of Science ®Google Scholar
• Swindle MM, Makin A, Herron AJ, Clubb FJ, Frazier KS. Swine as models in biomedical research and toxicology testing. Vet Pathol. 2012;49(2):344–356. doi:10.1177/0300985811402846
   PubMed Web of Science ®Google Scholar
• Chung CH. Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist. 2008;13(6):725–732. doi:10.1634/theoncologist.2008-0012
   PubMed Web of Science ®Google Scholar
• Peller M, Willerding L, Limmer S, et al. Surrogate MRI markers for hyperthermia-induced release of doxorubicin from thermosensitive liposomes in tumors. J Control Release. 2016;237:138–146. doi:10.1016/j.jconrel.2016.06.035
   PubMed Web of Science ®Google Scholar
• Manzoor AA, Lindner LH, Landon CD, et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 2012;72(21):5566–5575. doi:10.1158/0008-5472.CAN-12-1683
   PubMed Web of Science ®Google Scholar
• Institute S. Genomics of Drug Sensitivity in Cancer. 2020.
   Google Scholar
• Tan WS, Kelly JD. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol. 2018;15(11):667–685. doi:10.1038/s41585-018-0092-z
   PubMed Web of Science ®Google Scholar
• Chatterjee K, Zhang J, Honbo N, Karliner JS. Doxorubicin cardiomyopathy. Cardiology. 2010;115(2):155–162. doi:10.1159/000265166
   PubMed Web of Science ®Google Scholar
• Carvalho FS, Burgeiro A, Garcia R, Moreno AJ, Carvalho RA, Oliveira PJ. Doxorubicin-induced cardiotoxicity: from bioenergetic failure and cell death to cardiomyopathy. Med Res Rev. 2014;34(1):106–135.
   PubMed Web of Science ®Google Scholar
• Gabizon AA. Pegylated liposomal doxorubicin: metamorphosis of an old drug into a new form of chemotherapy. Cancer Invest. 2001;19(4):424–436. doi:10.1081/CNV-100103136
   PubMed Web of Science ®Google Scholar
• Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomedicine. 2006;1(3):297–315.
   PubMed Web of Science ®Google Scholar
• Guyton and Hall. Textbook of Medical Physiology. 2011:426–428.
   Google Scholar
• Csukás D, Urbanics R, Wéber G, Rosivall L, Szebeni J. Pulmonary intravascular macrophages: prime suspects as cellular mediators of porcine CARPA. Eur J Nanomed. 2015;7(1):27. doi:10.1515/ejnm-2015-0008
   Google Scholar
• Rafiyath SM, Rasul M, Lee B, Wei G, Lamba G, Liu D. Comparison of safety and toxicity of liposomal doxorubicin vs. conventional anthracyclines: a meta-analysis. Exp Hematol Oncol. 2012;1(1):10. doi:10.1186/2162-3619-1-10
   PubMedGoogle Scholar
• Schneberger D, Aharonson-Raz K, Singh B. Pulmonary intravascular macrophages and lung health: what are we missing? Am J Physiol Lung Cell Mol Physiol. 2012;302(6):L498–503. doi:10.1152/ajplung.00322.2011
   PubMedGoogle Scholar
• Fielding RM, Singer AW, Wang LH, Babbar S, Guo LS. Relationship of pharmacokinetics and drug distribution in tissue to increased safety of amphotericin B colloidal dispersion in dogs. Antimicrob Agents Chemother. 1992;36(2):299–307. doi:10.1128/AAC.36.2.299
   PubMed Web of Science ®Google Scholar
• Andersson M, Domellof L, Eksborg S, et al. Pharmacokinetics and central haemodynamic effects of doxorubicin and 4ʹepi-doxorubicin in the pig. Acta Oncol. 1989;28(5):709–714. doi:10.3109/02841868909092298
   PubMedGoogle Scholar
• August DA, Verma N, Vaertan MA, Shah R, Brenner DE. An evaluation of hepatic extraction and clearance of doxorubicin. Br J Cancer. 1995;72(1):65–71. doi:10.1038/bjc.1995.278
   PubMedGoogle Scholar
• Winkler GC. Pulmonary intravascular macrophages in domestic animal species: review of structural and functional properties. Am J Anat. 1988;181(3):217–234.
   PubMedGoogle Scholar
• Willerding L, Limmer S, Hossann M, et al. Method of hyperthermia and tumor size influence effectiveness of doxorubicin release from thermosensitive liposomes in experimental tumors. J Control Release. 2016;222:47–55. doi:10.1016/j.jconrel.2015.12.004
   PubMed Web of Science ®Google Scholar
• Allen TM, Hansen C. Pharmacokinetics of stealth versus conventional liposomes: effect of dose. Biochim Biophys Acta. 1991;1068(2):133–141.
   PubMedGoogle Scholar
• Szebeni J, Muggia F, Gabizon A, Barenholz Y. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev. 2011;63(12):1020–1030. doi:10.1016/j.addr.2011.06.017
   PubMed Web of Science ®Google Scholar
• Szebeni J, Simberg D, Gonzalez-Fernandez A, Barenholz Y, Dobrovolskaia MA. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol. 2018;13(12):1100–1108.
   PubMed Web of Science ®Google Scholar
• Swenson CE, Haemmerich D, Maul DH, Knox B, Ehrhart N, Reed RA. Increased duration of heating boosts local drug deposition during radiofrequency ablation in combination with thermally sensitive liposomes (ThermoDox) in a porcine model. PLoS One. 2015;10(10):e0139752.
   PubMed Web of Science ®Google Scholar
• Wood BJ, Poon RT, Locklin JK, et al. Phase I study of heat-deployed liposomal doxorubicin during radiofrequency ablation for hepatic malignancies. J Vasc Interv Radiol. 2012;23(2):248–255.e247. doi:10.1016/j.jvir.2011.10.018
   PubMed Web of Science ®Google Scholar
• Fülöp T, Kozma GT, Vashegyi I, et al. Liposome-induced hypersensitivity reactions: risk reduction by design of safe infusion protocols in pigs. J Control Release. 2019;309:333–338.
   PubMedGoogle Scholar